Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391747 | 1.00 | GPR84 (0.38) | GPR84MAOADRD2DRD4DRD3 | |
| SCHEMBL4687381 | 0.98 | GPR84 (0.35) | GPR84MAOADRD2DRD4DRD3 | |
| SCHEMBL269445 | 0.91 | — | — | |
| SCHEMBL8955030 | 0.89 | GPR84 (0.44) | GPR84MAOADRD2DRD4DRD3 | |
| SCHEMBL7003873 | 0.87 | GPR84 (0.41) | GPR84MAOADRD2DRD4DRD3 | |
| SCHEMBL269227 | 0.82 | — | — | |
| SCHEMBL25406384 | 0.79 | DAO (0.39) | GPR84MAOA | |
| SCHEMBL7976680 | 0.79 | GPR84 (0.38) | GPR84MAOADRD2DRD4DRD3 | |
| SCHEMBL5251062 | 0.79 | HRH1 (0.48) | MAOAHRH3 | |
| SCHEMBL25423256 | 0.79 | GPR84 (0.38) | GPR84MAOADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373661-B1 | NEW STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | LACER SA (ES) | 2013-03-20 | — | — | EP | disclosed |
| US-8106224-B2 | Stereospecific method for the preparation of dioxa-bicyclooctane nitrate compounds | LACER, S.A. (ES) | 2012-01-31 | — | — | US | disclosed |
| US-20110251409-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | LACER, S.A. (ES) | 2011-10-13 | — | — | US | disclosed |
| EP-2149577-B1 | New stereospecific method for the preparation of dioxa-bicyclooctane compounds | LACER SA (ES) | 2011-04-27 | — | — | EP | disclosed |
| US-20100160652-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | LACER, S.A. (ES) | 2010-06-24 | — | — | US | disclosed |
| EP-2199294-A1 | New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds | LACER, S.A. (ES) | 2010-06-23 | — | — | EP | disclosed |
| EP-2149577-A1 | New stereospecific method for the preparation of dioxa-bicyclooctane compounds | LACER, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| US-7635782-B1 | Stereospecific method for the preparation of dioxa-bicyclooctane compounds | LACER, S.A. (ES) | 2009-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251409-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | TST, NOS3, NOS1 | GPR84 2601/4885MAOA 255/4885DRD2 1335/4885 |
| US-20100160652-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | TST, NOS3, NOS1 | GPR84 2961/4885MAOA 303/4885DRD2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.